Status: Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.
Participants needed: 54
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Celcuity IncUpdated: Apr 13, 2026Locations: 13
Eligibility criteria
Adult males ≥18 years of age [+9]
History of malignancies other than adequately treated non-melanoma skin cancer o... [+4]